Mesenteric Arteriopathy in the Rat Induced by Phosphodiesterase III Inhibitors: An Investigation of Morphological,Ultrastructural,and Hemodynamic Changes

Abstract

A reproducible model of a phosphodiesterase III (PDE III) inhibitor-induced arteriopathy has been developed in the rat after subcutaneous administration of SK&F 95654. Administration of this potent PDE III inhibitor induced an arteriopathy of mesenteric arteries within 24 hr that was dose-related in intensity and incidence over the range 0.174, 0.348, 0.523, and 0.697 mmol/kg. The arteriopathy was restricted to muscular arteries of external diameter of 100-800 μm and was shown microscopically to be focal or segmental medial necrosis and hemorrhage. A time-course experiment, conducted from 3 to 24 hr postdosing, showed that the first changes observed 6 hr postdosing were on the endothelium followed by focal hemorrhages into the media at 12 hr postdosing, causing compression, degeneration, and necrosis of myocytes. From 16 hr postdosing, there was focal endothelial cell necrosis and loss of confluence. Leukocytes and activated platelets were found adhering to exposed basement lamina and seen to pass through endothelial gaps into the subintima. By 24 hr postdosing, medial necrosis was extensive with large areas of media replaced by erythrocytes, cell debris, and a few leukocytes and platelets.

The effect of 3 structurally dissimilar PDE III inhibitors administered subcutaneously at a dose of 0.697 mmol/kg was compared with that of SK&F 95654. The arteriopathy induced by these compounds were identical to that produced by SK&F 95654 with the incidence and severity of lesions ranked in the following order: SK&F 95654 > WIN 62582 > SK&F 94836, with no macroscopic lesions observed for SK&F 94120. Systolic blood pressure was measured for these 4 PDE III inhibitors at regular intervals over the 24-hr period postadministration by a plesthymographic method. The severity of the arterial lesions correlated with the magnitude of hypotension induced by these agents. It is postulated that the arterial damage is a consequence of profound vasodilation resulting in abnormal endothelial permeability and increased wall tension, resulting in progressive medial necrosis and hemorrhage.

Keywords

Vasodilator medial necrosis medial hemorrhage arterial distension

References

Bugelski PJ , Walsh Vockley CM , Sowinski JM , Arena E. , Berkowitz BA , and Morgan DG (1989). Ultrastructure of an arterial lesion induced in rats by fenoldopam mesylate, a dopaminergic vasodilator. Br. J. Exp. Pathol. 70: 153-165.

Burnstock G. (1970). Structure of smooth-muscle and its innervation . In: Smooth Muscle, E Bulbring , AF Brading et al (eds). Arnold, London, pp. 1-69.

Byrom FB (1969). The Hypertensive Vascular Crisis. Heinemann Medical Books Limited, London. Pp. 1ff.

Collins JJ , Elwell MR , Lamb JC , Manus AG IV , Heath JE , and Makovec TK (1988). Subchronic toxicity of orally-administered (gavage and dosed-feed) theophylline in Fischer 344 rats and B6C3F1 mice. Fund. Appl. Toxicol. 11: 472-484.

Cuenoud HF , Joris I. , Langer RS , and Majno G. (1987). Focal arteriolar insudation: A response of arterioles to chronic nonspecific irritation. Am. J. Pathol. 127: 592-604.

Evans DB , Potoczak RE , Steffen RP , Burmeister WE , McNish RW , Schenden JA , and Kaplan HR (1986). Cardiovascular pharmacology of the cardiotonic, imazodan (CI-914). Drug Dev. Res. 9: 143-157.

Gallagher PJ (1992). Blood vessels. In: Histology for Pathologists, SS Sternberg (ed). Raven Press, New York, pp. 195-213.

Giese J. (1964). Acute hypertensive vascular disease: Relation between blood pressure changes and vascular lesions in different forms of acute hypertension. Acta. Pathol. 62: 481-496.

Giese J. (1964). Acute hypertension vascular disease: 2. Studies on vascular reaction patterns and permeability changes by vital microscopy and colloidal tracer technique. Acta Pathol. 62: 497-515.

10.

Goldby FS and Beilin LJ (1972). How an acute rise in arterial pressure damages arterioles: Electron microscopic changes during angiotensin infusion. Cardiovasc. Res. 6: 569-584.

11.

Gristwood RW , Comer MB , Eden RJ , Taylor EM , Turner JA , Wallduck M. , and Owen DAA (1988). In vivo pharmacological studies with SK&F 94836, a potent inotrope/vasodilator with a sustained duration of action. Br. J. Pharmacol. 93: 893-901.

12.

Harleman JH , Joseph EC , Eden RJ , Walker TF , Major IR , and Lamb MS (1986). Cardiotoxicity of a new inotrope/vasodilator drug (SK&F 94120) in the dog. 1986 . Arch. Toxicol. 59: 51-55.

13.

Hegde SS and Lokhandwala MF (1988). Involvement of cyclic-AMP in the hypotensive response to fenoldopam but not to quinpirole in the anaesthetized rat. J. Auton. Pharmac. 8: 63-68.

14.

Isaacs KR , Joseph EC , and Betton GR (1989). Coronary vascular lesions in dogs treated with phosphodiesterase III inhibitors. Toxicol. Pathol. 17: 153-163.

15.

Johansson S. (1981). Cardiovascular lesions in Sprague-Dawley rats induced by long-term treatment with caffeine. Acta Pathol. Micro. Scand. Sect. A 89: 185-191.

16.

Joris I. , DeGirolami U. , Wortham K. , and Majno G. (1982). Vascular labelling with Monastral blue B. Stain Tech. 57: 177-183.

17.

Joseph EC , Jones HB , and Kerns WD (1996). Characterization of coronary arterial lesions in the dog following administration of SK&F 95654, a phosphodiesterase III inhibitor. Toxicol. Pathol. 24: 429-435.

18.

Kerns WD , Arena E. , Macia RA , Bugelski PJ , Matthews WD , and Morgan DG (1989). Pathogenesis of arterial lesions induced by dopaminergic compounds in the rat. Toxicol. Pathol. 17: 203-213.

19.

Limas C. and Westrum Band Limas CJ (1980). The evolution of vascular changes in the spontaneously hypertensive rat. Am. J. Pathol . 98: 357-384.

20.

Mesfin GM , Piper RC , DuCharme DW , Carlson RG , Humphrey SJ , and Zins GR (1989). Pathogenesis of cardiovascular alterations in dogs treated with minoxidil. Toxicol. Pathol. 17: 164-181.

21.

Mesfin GM , Shawaryn GG , and Higgins MJ (1987). Cardiovascular alterations in dogs treated with hydralazine. Toxicol. Pathol. 15: 409-416.

22.

Metz AL , Dominick MA , Suchanek G. , and Gough AW (1991). Acute cardiovascular toxicity induced by an adenosine agonist-antihypertensive in beagles. Toxicol. Pathol. 19: 98-107.

23.

Morgan DG , Bugelski PJ , Berkowitz BA , Valocik E. , and Arena E. (1983). Medial necrosis and hemorrhage in arteries of rats infused with dopaminergic agents. Lab. Invest. 48: 60A.

24.

Murray KJ , Eden RJ , Dolan JS , Grimsditch DC , Stutchbury CA , Patel B. , Knowles A. , Worby A. , Lynham JA , and Coates WJ (1992). The effect of SK&F 95654, a novel phosphodiesterase inhibitor, on cardiovascular, respiratory and platelet function. Br. J. Pharmacol. 107: 463-470.

25.

Nemes Z. , Dietz R. , Mann JFE , Luth JB , and Gross F. (1980). Vasoconstriction and increased blood pressure in the development of accelerated vascular disease. Virchows Arch. A. Pathol. Anat. Histol. 386: 161-173.

26.

Nordborg C. , Fredriksson K. , and Johansson BB (1985). Internal carotid and vertebral arteries of spontaneously hypertensive and normotensive rats. Acta Pathol. Microbiol. Immunol. Scand. [A] 93: 153-158.

27.

Ohlstein EH , Zabko-Potapovich B. , and Berkowitz BA (1984). Studies on vascular dopamine receptors with the dopamine receptor agonist: SK&F 82526. J. Pharmacol. Exp. Ther. 229: 433-439.

28.

Rhodin JAG (1980). Architecture of the vessel wall. In: Handbook of Physiology, DF Bohr , AP Somlyo , and HV Sparks (eds). American Physiological Society, Bethesda, Maryland, pp. 1-31.

29.

Robertson AL and Khairallah PA (1973). Arterial endothelial permeability and vascular disease the "Trap Door" effect. Exp. Mol. Pathol. 18: 241-260.

30.

Romanec P. and Wood LM (1989). The effects of differentially selective phosphodiesterase inhibitors on anaesthetized rat hind-quarter vascular resistance. Br. J. Pharmacol. 96(suppl.): 225P.

31.

Sandusky GE and Means JR (1987). Acute and subchronic toxicology of LY-195115 in rats and dogs. Tox. Letts. 38: 177-186.

32.

Sandusky GE , Vodicnik MJ , and Tamura RN (1991). Cardiovascular and adrenal proliferative lesions in Fischer 344 rats induced by long-term treatment with type III phosphodiesterase inhibitors (positive inotropic agents), isomazole and indolidan. Fund. Appl. Toxicol. 16: 198-209.

33.

Silver PJ (1991). Clinical status and regulatory issues of inotropes in congestive heart failure. Clin. Res. Pract. Drug Reg. Affairs 8: 225-238.

34.

Silver PJ , Hamel LT , Perrone MH , Bentley RG , Bushover CR , and Evans DB (1988). Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur. J. Pharmacol. 150: 85-94.

35.

Sokal RR and FJ Rohlf (1981). Biometry. W. H. Freeman, San Francisco, pp. 561-616.

36.

Tanaka T. , Ishikawa T. , Hagiwara M. , Onoda K. , Itoh H. , and Hidaka H. (1988). Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 36: 313-320.

37.

Thorball N. and Olsen F. (1974). Ultrastructural pathological changes in intestinal submucosal arterioles in angiotensin-induced acute hypertension in rats. Acta Pathol. Micro. Scand. Sect. A 82: 703-713.

38.

Westwood FR , Iswaran TJ , and Greaves P. (1990). Pathologic changes in blood vesels following administration of an inotropic vasodilator (ICI 153,110) to the rat. Fund. Appl. Toxicol. 14: 797-809.

39.

Wiener J. and Giacomelli F. (1973). The cellular pathology of experimental hypertension. VII. Structure and permeability of the mesenteric vasculature in angiotensin-induced hypertension. Am. J. Pathol. 72: 221-240.

40.

Yuhas EM , Morgan DG , Arena E. , Kupp RP , Saunders LZ , and Lewis HB (1985). Arterial medial necrosis and hemorrhage induced in rats by intravenous infusion of fenoldopam mesylate, a dopaminergic vasodilator . Am. J. Pathol. 119: 83-91.